04 · Five things to know · 04
Regeneron’s Livsayis, an RNAi drug discovered by Alnylam, was approved for generalized myasthenia gravis
Know it
What happened
Alnylam said on 11.19 that FDA approved Livsayis (cemdisiran), from its collaborator Regeneron, for adults with generalized myasthenia gravis who test positive for antibodies to the acetylcholine receptor. It silences C5, a complement protein, and is given under the skin four times a year. Alnylam calls it the first RNAi therapy for the disease and the seventh approved drug discovered by Alnylam, and it receives a $25M milestone and royalties of up to 15%. FDA’s novel approvals list dates the approval itself to 11.18. Claim
C5 blockade is already used in this disease; dosing four times a year is the difference the companies stress. We did not read the label. Analysis
Sources
Alnylam release on Business Wire, read through Yahoo Finance (11.19) (opens another website in a new tab) Co; PharmExec (opens another website in a new tab) Press
Also in Five things to know
- Erasca’s pan-RAS pill ERAS-0015 drew confirmed responses in 44% of 25 previously treated pancreatic cancer patients
- Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer
- Actinogen’s pivotal Xanamem trial in Alzheimer’s disease missed its primary endpoint
- AbbVie took an option on AND-gated bispecifics from DISCO; Bloomberg reports Sanofi is weighing a bid for Insmed
Bookmarks need a Mind Club sign-in. How sign-in works
Read it in Five things to know